\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Metabolic Syndrome in Bangladeshi Patients of Rheumatoid Arthritis}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2016-01-15 (revised: 15 January 2016)} \def\TheID{\makeatother } \def\TheDate{2016-01-15} \title{Metabolic Syndrome in Bangladeshi Patients of Rheumatoid Arthritis} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Dr. Md. Abu Hanifa} \author[2]{Aziza Sultana} \author[3]{Saimun Naher} \author[4]{Bimal Chandra Roy} \author[5]{Shafiul Alam} \affil[1]{ Rangpur Medical College Hospital, Rangpur, Bangladesh} \renewcommand\Authands{ and } \date{\small \em Received: 7 December 2015 Accepted: 3 January 2016 Published: 15 January 2016} \maketitle \begin{abstract} Background: Rheumatoid arthritis (RA) is a chronic inflammatory disorder of unknown etiology, characterized by systemic symptoms that particularly involve the joints and may lead to deformities during the course of the disease. It is the most common persistent inflammatory arthritis, occurring throughout the world and in all ethnic groups.Objectives: To find out the association of metabolic syndrome in rheumatoid arthritis patients as compared to healthy individuals.Methods: This case control study was carried out with 50 patients of rheumatoid arthritis (case) and 50 apparently healthy individual (controls) in Biochemistry Department, Dhaka Medical College, Dhaka from July 2014 to June 2015. After overnight fast (at least 8 hrs) venous sample was taken from each subject. \end{abstract} \keywords{rheumatoid arthritis, metabolic syndrome, patients, biochemistry department, bangladesh.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{I. Introduction}]{I. Introduction}\par heumatoid Arthritis (RA) is a chronic inflammatory disorder of unknown etiology, characterized by systemic symptoms that particularly involve the joints and may lead to deformities during the course of the disease \hyperref[b0]{1} . It is the most common persistent inflammatory arthritis, occurring throughout the world and in all ethnic groups. The prevalence is lowest in Black Africans and Chinese and highest in Pima Indians. In Caucasians, approximately 0.8-1.0\% is affected, with a female to male ration of 3:1. The clinical course is prolonged, with intermittent exacerbations and remissions \hyperref[b1]{2} .\par The established RA can be distinguished from other forms of arthritis by multiple criteria; and those agreed by the American Rheumatism Association. The median prevalence estimate the RA for the total population in South European Countries is 3.3 cases per 1000, and for developing countries 3.5 cases per 1000 \hyperref[b3]{3} . RA affects 0.5-1.0\% of adults in developed countries and is 2-3 times more frequent in women than men \hyperref[b4]{4} . The onset is most frequent during the fourth and fifth decades of life with 80\% of all patients developing the disease between the ages of 35-50 years \hyperref[b5]{5} . The overall prevalence of RA in Bangladesh is 0.7\% in rural population and 0.4\% in urban population \hyperref[b6]{6} .\par RA is considered an autoimmune disease \hyperref[b7]{7} and the overall systemic and articular inflammatory load drives the destructive progression of the disease. In addition, the extent of inflammation has been linked to an increased risk of cardiovascular mortality in patients with RA as compared to general population \hyperref[b8]{8} . This is because the patients with RA are more prone for accelerated atherosclerosis which in turn is a risk factor for cardiovascular disease and thus there decreased survival in them \hyperref[b9]{9} .\par The metabolic syndrome is considered as one of the best known risk factors to the development of CVD. The autoimmune systemic inflammatory response, along with the presence of metabolic syndrome doubles the risk for fatal or non fatal CVD and coronary atherosclerosis, regardless of age and sex \hyperref[b10]{10} . Rheumatoid arthritis has been associated with increased prevalence of metabolic syndrome, but its role in the different characteristics of the disease, such as disease duration, activity and treatment with glucocorticoids, is not well defined from a clinical point of view, the relevance of metabolic syndrome derives from its strong association with the occurrence of subclinical atherosclerosis, major adverse cardiovascular events and death. Atherosclerosis, the main determinant of CV morbidity, and mortality occurs prematurely in RA. Patients with RA have an increased risk for CVD. Metabolic syndrome occurs up to 45\% of RA patients \hyperref[b11]{11,} {\ref 12} .\par Metabolic syndrome previously known as syndrome X constitutes a cluster of abnormalities including abdominal obesity, insulin resistance, hypertension, hypertriglyceridemia and decreased high density lipoprotein cholesterol \hyperref[b13]{13} and recognized it as multiplex of risk factors for cardiovascular diseases \hyperref[b14]{14} . Syndrome X has now been re-designated as metabolic syndrome after WHO named it so in 1999. WHO included several parameters as the diagnostic criteria for metabolic syndrome such as presence of diabetes mellitus, hypertension, hypertriglyceridemia and low serum HDL-cholesterol and high BMI. The National Cholesterol Education programmes adult treatment panel III (NCEP-ATP III) report identified the metabolic syndrome as a multiplex of risk factors for cardiovascular diseases that deserve more clinical attention \hyperref[b15]{15} . Modified NCEP-ATP III for metabolic syndrome includes raised fasting plasma glucose, hypertension, hypertriglyceridemia low serum HDL-Cholesterol and increased waist circumference \hyperref[b13]{13} .\par Proinflammatory cytokines, tumour necrosis factor alpha (TNF-?), interleukin-6 (lL-6) seen in patients with RA contribute to insulin resistance which is the basic metabolic disorder seen in metabolic syndrome. Insulin resistance leads to other metabolic disturbances, like hyperglycaemia, dyslipidemia \hyperref[b16]{16} which independently contribute to atherosclerosis and cardiovascular risk.\par The basic pathology in RA is inflammation which in turn is the basis of atherosclerosis and this has led to study the relationship between systemic inflammatory conditions such as RA and the risk for CVD. It was seen that even in the absence of traditional coronary risk factors, women with RA have a 2-3 fold higher risk of CVD \hyperref[b17]{17} . Also another study showed that patients with RA are 50\% more likely to suffer a cardiovascular event than subjects from the general population \hyperref[b18]{18} .\par Present study was designed in a small group of Bangladeshi population to observe the association of metabolic syndrome in patients of Rheumatoid Arthritis. \section[{II. Objective of the Study}]{II. Objective of the Study}\par The main objective of this study was to find out the association of metabolic syndrome in rheumatoid arthritis patients as compared to healthy individuals. \section[{III. Materials and Methods}]{III. Materials and Methods}\par This is a case control study and conducted from July 2014-June 2015 in the Department of Biochemistry, Dhaka Medical College, Dhaka, Bangladesh. Study population included 50 adult diagnosed cases of rheumatoid arthritis attending in Department of Medicine of Dhaka Medical College Hospital, Dhaka and 50 apparently healthy individuals (attendants of patients and stuff members of the hospital) as control. Sample Size was one hundred and purposive sampling was done. Rheumatoid arthritis patients were selected as per inclusion and exclusion criteria. Diagnoses were done on the basis of revised criteria of ACR 2010 including: 1. Compatible clinical history. 2. Physical examination of the patients. 3. Laboratory investigation in selected cases (ESR, CRP, RF, X-ray, Anti-CCPA). Controls were selected by age and sex matched apparently healthy men and women. After selection of the subjects, the objectives, natures, purpose and potential risk of all procedures used for the study were explained in details and informed written consent were taken from both the patients or attendants and the control. Particulars, detail history, clinical examination, physical and anthropometric measurements were taken in a predesigned data collection form, from all the cases and controls .All data were recorded in a predesigned data collection sheet. Continuous variables were expressed as mean ± SD and were compared between groups of patients by student's 't' test. Categorical variables were compared using a chi-square test or Fischer's exact test as appropriate, and were presented as absolute frequencies with percentages. All p values were twotailed with significance defined as p < 0.05 at the level of 95\% confidence interval. All analysis was done using the SPSS version 21 package for windows. \section[{IV. Results}]{IV. Results}\par Out of total 100 study subjects, 50 were RA cases and 50 were apparently healthy controls. Following results were found in this study-Mean age was 41.94 (SD±8.57) years in case and 39.62 (SD±9.26) years in control. The case and control groups were age matched. In both groups maximum study subjects were in age group 41-50 years. In case maximum 22 (44.0\%) patients were in age group 41-50 years and similarly in control group maximum 20 (40.0) patients were in same group. Difference between two group was not statistically significant (p>0.05). In both groups female was predominant than male. The case and control groups were sex matched. When comparison of different anthropometric components of metabolic syndrome (BP \& WC) in case and control according to NCEP-ATPIII 2004. There were statistical significant difference in BP and WC between case and control. Mean of systolic BP, Diastolic BP, WC and BMI were significantly higher in case group than control group. \section[{Volume XVI Issue 1 Version I}]{Volume XVI Issue 1 Version I}\par Mean fasting plasma glucose and Triglyceride were significantly higher in case group than control group and HDL-C was significantly lower in case group than control group. Mean of total cholesterol and LDL-C were almost same in both groups. \section[{Table II : Comparison of Fasting Plasma Glucose and Lipid Profile between case and control}]{Table II : Comparison of Fasting Plasma Glucose and Lipid Profile between case and control}\par Unpaired t-test was done to measure the level of significance, p < 0.05 was significant In comparison to different biochemical components of metabolic syndrome (FPG, HDL-C \& TG) in case and control according to NCEP-ATP III 2004, there were statistical significant difference in FPG, HDL-C and TG between case and control. Chi square test was done to measure the level of significance. p < 0.05 was significant V. \section[{Discussions}]{Discussions}\par Rheumatoid Arthritis is a systemic inflammatory disorder characterized by chronic symmetric and erosive synovitis that preferentially affects peripheral joints, with a prevalence of 0.5-1\% in the population \hyperref[b19]{19} . Emerging epidemiological evidence suggests that CVDs account for approximately 50\% of all RA associated deaths \hyperref[b20]{20} .\par Metabolic Syndrome is a cluster of cardiovascular risk factors including central obesity, atherogenic dyslipidemia, hypertension and glucose intolerance, and is a strong predictor of cardiovascular diseases, diabetes and stroke \hyperref[b21]{21} . Overlapping inflammatory pathways and genetic susceptibility may be potential biologic links underlying this association \hyperref[b22]{22} .\par The age of the study participants ranged from (20-60) years. The mean age was found 41.91±8.57 years in cases and 39.62 ±9.26 years in control group. The mean age difference was not found statistically significant (p=0.197).\par In the case group 17(34.0\%) cases were males and 33 (66.0\%) cases were females. In the control group there were 23 (46.0\%) were males and 27(54.0\%) were females the difference of male female ration was not found statistically significant (p=0.221) between two groups. This observation was consistent with the result of the study \hyperref[b23]{23} . They observed that age and sex are not important risk factors for metabolic syndrome.\par Increased waist circumference (Abdominal obesity) was a notable feature in our study which was found 84.5±10.3 cm in cases and 80.0±9.1 cm in controls, which showed significant difference between two groups (p=0.025) statistically. This result is in agreement with that of other previous study 24, \hyperref[b25]{25} .\par In our study, it is observed a higher prevalence of metabolic syndrome among RA patients than the controls (44\% Vs 16\%, p=0.002), which was similar to the results of well designed studies {\ref 24,}\hyperref[b26]{26} .\par These findings tend to support that, there is an association between RA and Metabolic syndrome in hospital based RA patients in Bangladesh, which gives an insight into the pattern of co-morbidities of RA in our country.\par In our study, the prevalence of high blood pressure was significantly high in cases than in controls. The mean systolic Blood pressure was 132.7±12.46 mm of Hg in cases and 120.3±8.33 mm of Hg in controls (p=0.001) and the mean diastolic BP was 83.9±8.8 mm of Hg in cases and 74.9±6.7 mm of Hg in controls (p=0.001). The difference was statistically significant. These observation were consistent with the results of the others studies \hyperref[b26]{26,}\hyperref[b27]{27} . Possible explanation may be, insulin resistance or obesity activates sympathetic nervous system and renin-angiotensin aldosteron system which subsequently results in hypertension.\par Increased fasting plasma glucose was the most predominant feature (66\%) contributing to increased prevalence of metabolic syndrome in RA group in our study and it was significantly higher in cases than controls (66\% Vs 4\%). This result is supported by several previous studies.\par In our study, it was observed that 36\% patients had presented with hypertriglceridemia in case group and 6\% in control group which was statistically significant (p=0.001). In some studies 24,26 found insignificant difference of triglyceride level between case and control and another study \hyperref[b23]{23} found triglyceride is significantly higher in control group in their study.\par Regarding HDL-C, which is one of the biochemical components of metabolic Syndrome, it was found that 96\% of cases had reduced HDL-C in case group whereas it was 66\% in control group which was statistically significant (p=0.001), which was consistent with the findings of other studies 24,28 . \section[{VI. Limitations}]{VI. Limitations}\par We have some limitations of this study like-? Small sample size, which may reduce the strength of the study. ? The sample was taken purposively, so there may be a chance of bias which can influence the result. \section[{VII. Conclusion}]{VII. Conclusion}\par Although a broad and evolving literature supports that RA is associated with metabolic syndrome, the association as well as their causal relationship is still unsettled. Exploration of these associations has practical consequence in the management of both the disorders. In conclusion this study revealed that metabolic syndrome is associated with RA. Therefore, in addition to the evaluation of RA, metabolic syndrome should be sort out in all RA patients to reduce impending cardiovascular events. \begin{figure}[htbp] \noindent\textbf{3}\includegraphics[]{image-2.png} \caption{\label{fig_0}Figure 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{I} \par \begin{longtable}{P{0.6598173515981735\textwidth}P{0.07568493150684931\textwidth}P{0.09121004566210045\textwidth}P{0.02328767123287671\textwidth}} \multicolumn{2}{l}{In case group, 22 (44.0\%) patients had}\tabcellsep \tabcellsep \\ \multicolumn{2}{l}{metabolic syndrome and in control group only 8 (16.0\%)}\tabcellsep \tabcellsep \\ \multicolumn{2}{l}{subjects had metabolic syndrome. The difference}\tabcellsep \tabcellsep \\ \multicolumn{2}{l}{between these two groups was statistically significant}\tabcellsep \tabcellsep \\ (p<0.05).\tabcellsep \tabcellsep \tabcellsep \\ Metabolic syndrome\tabcellsep Case n (\%)\tabcellsep Group Control n (\%)\tabcellsep p value\\ Yes\tabcellsep 22 (44.0)\tabcellsep 8 (16.0)\tabcellsep \\ No\tabcellsep 28 (56.0)\tabcellsep 42 (84.0)\tabcellsep 0.002\\ Total\tabcellsep 50 (100.0)\tabcellsep 50 (100.0)\tabcellsep \\ \multicolumn{4}{l}{Chi-square test was done to measure the level of significance, p < 0.05 was significant}\\ Year 2016\tabcellsep \tabcellsep \tabcellsep \\ D D D D ) I\tabcellsep \tabcellsep \tabcellsep \\ (\tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_0}Table I :}\end{figure} \begin{figure}[htbp] \noindent\textbf{III} \par \begin{longtable}{P{0.16492537313432837\textwidth}P{0.15646766169154228\textwidth}P{0.028544776119402985\textwidth}P{0.0021144278606965174\textwidth}P{0.004228855721393035\textwidth}P{0.0021144278606965174\textwidth}P{0.15012437810945273\textwidth}P{0.050746268656716415\textwidth}P{0.10149253731343283\textwidth}P{0.08246268656716418\textwidth}P{0.10677860696517413\textwidth}} \tabcellsep \multicolumn{4}{l}{Male > 40 mg/dl / Female > 50 mg/dl}\tabcellsep \tabcellsep 2 (4)\tabcellsep \multicolumn{2}{l}{17 (34)}\\ TG\tabcellsep ? 150 mg/dl < 150 mg/dl\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 18 (36) 32 (64)\tabcellsep \multicolumn{2}{l}{3 (6) 47 (94)}\tabcellsep 0.001\tabcellsep 8.81 (2.39 -32.04)\\ \tabcellsep \tabcellsep 70 80 90\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 84\tabcellsep Year 2016\\ \tabcellsep Percentage\tabcellsep 0 10 20 30 40 50 60\tabcellsep 44\tabcellsep Case\tabcellsep 56\tabcellsep Yes No\tabcellsep 16\tabcellsep Control\tabcellsep Volume XVI Issue 1 Version I\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep D D D D ) I\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep (\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Group}\\ \tabcellsep \multicolumn{2}{l}{FPG and Lipid Profile}\tabcellsep \tabcellsep \tabcellsep \tabcellsep Case\tabcellsep \tabcellsep \tabcellsep Control\tabcellsep p value\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep (Mean ± SD)\tabcellsep \tabcellsep \multicolumn{2}{l}{(Mean ± SD)}\\ \multicolumn{3}{l}{Fasting Plasma Glucose (mmol/l)}\tabcellsep \tabcellsep \tabcellsep \tabcellsep 6.52 ± 1.93\tabcellsep \tabcellsep \multicolumn{2}{l}{4.66 ± 0.95}\tabcellsep 0.001\\ \multicolumn{3}{l}{Total Cholesterol (mg/dl)}\tabcellsep \tabcellsep \tabcellsep \tabcellsep 181.06 ± 30.38\tabcellsep \tabcellsep \multicolumn{2}{l}{177.40 ± 27.77}\tabcellsep 0.531\\ \multicolumn{2}{l}{HDL-C (mg/dl)}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 34.88 ± 7.02\tabcellsep \tabcellsep \multicolumn{2}{l}{42.72 ± 7.02}\tabcellsep 0.001\\ \multicolumn{2}{l}{LDL-C (mg/dl)}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 118.34 ± 30.53\tabcellsep \tabcellsep \multicolumn{2}{l}{110.40 ± 26.78}\tabcellsep 0.170\\ \multicolumn{2}{l}{Triglyceride (mg/dl)}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 137.02 ± 40.74\tabcellsep \tabcellsep \multicolumn{2}{l}{112.72 ± 37.76}\tabcellsep 0.003\\ \multicolumn{5}{l}{Biochemical components of metabolic syndrome}\tabcellsep \tabcellsep Group\tabcellsep \tabcellsep \\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Case\tabcellsep \multicolumn{2}{l}{Control}\tabcellsep p value\tabcellsep OR (95\% CI)\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep n (\%)\tabcellsep \tabcellsep n (\%)\\ \tabcellsep ? 5.6 mmol/L\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 33 (66)\tabcellsep \tabcellsep 2 (4)\\ FPG\tabcellsep < 5.6 mmol/L\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 17 (34)\tabcellsep \multicolumn{2}{l}{48 (96)}\tabcellsep 0.001\tabcellsep 46.58 (10.08-215.31)\\ HDL-C\tabcellsep \multicolumn{4}{l}{Male ? 40 mg/dl / Female ? 50 mg/dl}\tabcellsep \tabcellsep 48 (96)\tabcellsep \multicolumn{2}{l}{33 (66)}\tabcellsep 0.001\tabcellsep 12.36 (2.67 -57.13)\end{longtable} \par {\small\itshape [Note: © 2016 Global Journals Inc. (US)]} \caption{\label{tab_1}Table III :}\end{figure} \footnote{© 2016 Global Journals Inc. (US)} \backmatter \subsection[{Conflict of Interests}]{Conflict of Interests}\par The authors declare that there is no conflict of interests regarding the publication of this paper. \subsection[{VIII. Acknowledgement}]{VIII. Acknowledgement}\par It is a great pleasure to acknowledge our profound gratitude and honor to Dr. Mohammad \begin{bibitemlist}{1} \bibitem[Edinburgh and Livingstone]{b2}\label{b2} \textit{}, Churchill Edinburgh , Livingstone . Elservier. 2014 p. . \bibitem[ Scand J Rheumatol]{b28}\label{b28} \textit{}, \textit{Scand J Rheumatol} 41 p. . \bibitem[Van Doornum et al. ()]{b11}\label{b11} ‘Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?’. S Van Doornum , G Mccoll , I P Wicks . \textit{Arthritis Rheum} 2002. 46 p. . (PubMed) \bibitem[Goshayeshi et al. ()]{b20}\label{b20} ‘Association between metabolic syndrome, BMI, and serum Vitamin D concentrations in rheumatoid arthritis’. L Goshayeshi , H R Saber , M Sahebari , Z Rezaieyazdi , H Rafatpanah . \textit{Clin Rheumatol} 2012. 31 p. . \bibitem[Grundy et al. ()]{b15}\label{b15} ‘Definition of metabolic syndrome: Report of the National Heart, Lungh, and Blood Institute’. S M Grundy , H B Brewer , J I Cleeman , S C SmithJr , C Lenfant . \textit{Circulation} 2004. 109 (3) p. . \bibitem[Fischer et al. ()]{b17}\label{b17} ‘Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of firsttime acute myo-cardial infarction'’. L M Fischer , R G Schlienger , C Matter , H Jick , C R Meier . \textit{Am J Cardiol} 2004. 93 p. . \bibitem[Mittelman et al. ()]{b16}\label{b16} ‘Extreme insulin resistance of the central adipose depot in vivo’. S D Mittelman , G W Van Citters , E L Kirkman , R N Bergman . \textit{Diabetes} 2002. 5 p. . \bibitem[Alamanos et al. ()]{b3}\label{b3} ‘Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of a systematic review’. Y Alamanos , P V Voulgari , A A Drosos . \textit{Semin Arthritis Rheum} 2006. 36 p. . \bibitem[Crowson et al. ()]{b25}\label{b25} ‘Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease’. C S Crowson , E Myasoedova , J M Davis , Iii , E L Matteson , V L Roger . \textit{J Rheumatol} 2011. 38 p. . \bibitem[Stevens et al. ()]{b12}\label{b12} ‘Inflammation and atherosclerosis in rheumatoid arthritis’. R J Stevens , K M Douglas , A N Saeatzis . \textit{Expert Rev Mol Med} 2005. 7 p. . (PubMed) \bibitem[Manzi and Wasko ()]{b9}\label{b9} ‘Inflammationmedicated diseases and atherosclerosis’. S Manzi , M C Wasko . \textit{Ann Rheum Dis} 2000. 59 p. . \bibitem[Lipsky et al. ()]{b5}\label{b5} ‘Inflaximab and methtroxate in the treatment of rheumatoid arthritis’. P E Lipsky , D M Vender Heigde , E W St Clain , D E Furst , F C Breedveld , J R Kalden . \textit{N Engl J Med} 2000. 343 p. . \bibitem[Sahebari et al. ()]{b23}\label{b23} ‘Investigation of the association between metabolic syndrome and disease activity in rheumatiod arthritis’. M Sahebari , L Goshayeshi , Z Mirfeizi . \textit{The Scientific World Journal} 2011. 11 p. . (View at publisher. View at google Scholar. View at Scopus) \bibitem[Wilson et al. ()]{b21}\label{b21} \textit{Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus}, P W Wilson , R B Agostino , H Parise . 2005. 112 p. . \bibitem[Cojocaru et al. ()]{b10}\label{b10} ‘Metabolic syndrome in rheumatoid arthritis’. M Cojocaru , I M Cojocaru , I Silosi , C D Vrabie . \textit{Maedica (Buchar)} 2012. 7 p. . \bibitem[Metabolic syndrome in rheumatoid arthritis: case control study Metabolic Syndrome in Bangladeshi Patients of Rheumatoid Arthritis Hassouni ()]{b24}\label{b24} ‘Metabolic syndrome in rheumatoid arthritis: case control study’. \textit{Metabolic Syndrome in Bangladeshi Patients of Rheumatoid Arthritis Hassouni}, 2013. \bibitem[Karvounaris et al. ()]{b29}\label{b29} ‘Metabolic syndrome is common among rniddle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study'’. S A Karvounaris , P I Sidiropoulos , J A Papadakis , E K Spanakis , G . Bertsias , H D Kritikos . \textit{Ann Rheum Dis} 2007. 66 (1) p. . \bibitem[Da Chunha et al. ()]{b27}\label{b27} \textit{Metabolic syndrome prevalance is increased in rheumatoid arthritis patients and is associated with disease activity}, V R Da Chunha , C V Brenol , J C Brenol , S C Fuchs , E M Arlindo . 2012. \bibitem[Smolen et al. ()]{b7}\label{b7} ‘New therapies for the treatment of rheumatoid arthritis’. J S Smolen , D Aletaha , M Koeller , M Weisman , P Emery . \textit{Lancet} 2007. 370 p. . \bibitem[Kojima et al. ()]{b0}\label{b0} ‘Phychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis’. M Kojima , T Kojima , N Ishiguro , T Oguchi , M Oba , H Tsuchiya , F Sugiura . \textit{J Psychosom Res} 2009. 67 (5) p. . \bibitem[Dhanraj et al. ()]{b13}\label{b13} ‘Prevalence and predictors of metabolic syndrome in nonobese Asian Indians with mewly detected type 2 diabetes mellitus’. E Dhanraj , A Bhansali , S Jaggi , P Dutta , S Jain , P Tiwari . \textit{J ind Med Assoc} 2005. 106 p. . \bibitem[Haq et al. ()]{b6}\label{b6} ‘Prevalence of rheumatic disease and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study’. S A Haq , J Darmawan , M N Islam , M Z Uddin , B B Das , F Rahman . \textit{J. Rheumatil} 2005. 32 p. . \bibitem[Scott et al. ()]{b4}\label{b4} ‘Rheumatoid arthritis’. D L Scott , F Wolfe , T W Huizinga . \textit{Lancet} 2010. 376 p. . \bibitem[Ralston and Mclnnes (ed.) ()]{b1}\label{b1} \textit{Rheumatology and Bone}, S H Ralston , I B Mclnnes . Walker B.R., Colledge N.R., Ralston S.H., Penman I.D. (ed.) 2014. (Davidson's principle \& practice of medicine 22 nd edition) \bibitem[Avina-Zubieta et al. ()]{b18}\label{b18} ‘Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies'’. J A Avina-Zubieta , H K Choi , M Sadatsafavi , M Etminan , J M Esdaile , D Lacaille . \textit{Arthritis Rheum} 2008. 59 p. . \bibitem[Reaven ()]{b14}\label{b14} \textit{Role of insulin resistance in human disease}, G M Reaven . 1988. 37 p. . (Banting lecture 1988) \bibitem[Gabriel ()]{b19}\label{b19} ‘The epidemiology of rheumatoid arthritis’. S E Gabriel . \textit{Rheum Dis Clin North Am} 2001. 27 p. . \bibitem[Karakok et al. ()]{b26}\label{b26} ‘The relationship of metabolic syndrome with disease activity and the functional status in patients with Rheumatoid Arthritis'’. M Karakok , I Batmaz , M A Sariyildiz , M Tantasiz , R Cevik . \textit{Clin Med Res} 2012. 4 p. . \bibitem[Gelfand et al. ()]{b22}\label{b22} ‘The risk of lymphoma in patients with psoriasis'’. J M Gelfand , D B Shin , A L Neimann , X Wang , D J Margolis , A B Troxel . \textit{Journal of Investigative Dermatoogy} 2006. 126 p. . \bibitem[Meune et al. ()]{b8}\label{b8} ‘Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-annalysis of cohort studies’. C Meune , E Touze , L Trinquart , Y Allanore . \textit{Rheumatology (Oxford)} 2009. 48 p. . \end{bibitemlist} \end{document}